Noreen Henig - 24 Jul 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Chief Medical Officer
Signature
/s/ Marc Belsky, Attorney-in-Fact
Issuer symbol
KZR
Transactions as of
24 Jul 2023
Net transactions value
$0
Form type
4
Filing time
26 Jul 2023, 17:02:56 UTC
Previous filing
20 Jun 2023
Next filing
14 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -300,000 -100% 0 24 Jul 2023 Common Stock 300,000 $4.56 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Award +300,000 300,000 24 Jul 2023 Common Stock 300,000 $2.28 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -280,000 -100% 0 24 Jul 2023 Common Stock 280,000 $5.45 Direct F2, F3
transaction KZR Employee Stock Option (right to buy) Award +280,000 280,000 24 Jul 2023 Common Stock 280,000 $2.28 Direct F2, F3
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -180,000 -100% 0 24 Jul 2023 Common Stock 180,000 $14.55 Direct F2, F4
transaction KZR Employee Stock Option (right to buy) Award +180,000 180,000 24 Jul 2023 Common Stock 180,000 $2.28 Direct F2, F4
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -220,000 -100% 0 24 Jul 2023 Common Stock 220,000 $6.84 Direct F2, F5
transaction KZR Employee Stock Option (right to buy) Award +220,000 220,000 24 Jul 2023 Common Stock 220,000 $2.28 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vested on May 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
F3 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
F4 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
F5 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.